Molecular therapy for pulmonary arterial hypertension: Clopidogrel(brand name: Plavix), a drug used to treat myocardial disorders, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 28/January/2018, 10.19 pm

Natural product-based exercise mementics therapy for Metabolic disease: 18β-Glycyrrhetinic acid [(18β-GA) Enoxolone], isolated from glycyrrhiza glabra/Licorice, increases PPARδ  and Foxo1 levels, inhibits glucose catabolism, preserves glucose levels, stimulates FA catabolism, delays the onset of hypoglycemia and boosts endurance exercise via down regulation of its target gene, 27/January/2018, 11.41 pm
January 27, 2018
Lifespan extension therapy: Lansoprazole (Brand name: Prevacid), a drug used in the treatment of stomach ulcers, prolongs mammalian life span via down regulation of angiotensin II type I receptor (AT1R), 28/January/2017, 10.37 pm
January 28, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for pulmonary arterial hypertension: Clopidogrel (brand name: Plavix), a drug used to treat myocardial disorders, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3


Significance of the study:  

Clopidogrel  has been shown to shown to treat myocardial disorders. However, its mechanism of action is far from understood. 

This study suggests, for the first time, that Clopidogrelby increasing the expression of its target gene, it may decrease, in dose-dependent manner, the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, pharmacological formulations encompassing Clopidogrel or its analogues, either alone or in combination with other drugs, may be used to treat pulmonary arterial hypertension (Figure 2).

Figure 1. Mechanistic insights into how Clopidogrel inhibits the development of pulmonary hypertension through regulation of its target genes

Figure 2. The chemical structure of Clopidogrel.


Details of the research findings: 

Idea Proposed/Formulated by:

Dr L Boominathan Ph.D.

Undisclosed mechanistic information: How Clopidogrel  decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Molecular therapy for pulmonary arterial hypertension: Clopidogrel(brand name: Plavix), a drug used to treat myocardial disorders, inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 28/January/2018, 10.19 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.